What Domperidone GSK treats: main uses and benefits

Domperidone GSK is a medication primarily used to manage symptoms associated with upper gastrointestinal motility disorders. Its therapeutic effects are focused on improving the coordination of the digestive system to alleviate specific types of physical discomfort.

Relief of Nausea and Vomiting

The most common use of Domperidone GSK is for the short-term relief of nausea and vomiting. These symptoms may arise from various causes, and the medication works by targeting the mechanisms that trigger the urge to vomit and the sensation of sickness.

Management of Gastric Discomfort

Domperidone GSK is also utilized to treat symptoms of gastric heaviness and upper abdominal discomfort. It is specifically designed to address conditions where the stomach does not empty efficiently, a process known as delayed gastric emptying. By aiding the movement of food through the digestive tract, it helps reduce the following sensations:

• Early satiety: Feeling full shortly after beginning a meal.
• Bloating: A sensation of excessive fullness or pressure in the upper abdomen.
• Epigastric pain: Discomfort or aching located in the upper central region of the abdomen.
• Regurgitation: The backflow of stomach contents into the esophagus.

Mechanism of Action

As a dopamine antagonist, Domperidone GSK works by blocking dopamine receptors in the gastrointestinal tract and the area of the brain responsible for the vomiting reflex. In the digestive system, this action increases the strength and frequency of contractions in the stomach and small intestine. This ensures that food moves more consistently through the stomach and into the bowel, preventing the stagnation that leads to nausea and feelings of heaviness.

Regulatory References

1. Health Canada Product Monograph

Regulatory documents strictly define the patient populations eligible to use Domperidone GSK due to concerns regarding cardiac risk.

Eligibility Criteria

Contraindicated Conditions and Co-Medications

Domperidone is strictly contraindicated for use in patients with:

• Known existing prolongation of cardiac conduction intervals (e.g., QTc), significant electrolyte disturbances (e.g., hypokalaemia), or underlying cardiac diseases such as congestive heart failure.
• Conditions where stimulating gastric motility would be harmful (e.g., gastrointestinal haemorrhage, mechanical obstruction, or perforation).
• Co-administration with QT-prolonging medicines (excluding apomorphine under precautions) or potent CYP3A4 inhibitors (drugs that slow the breakdown of domperidone).

Use is generally restricted to the lowest effective dose for the shortest duration, typically not exceeding one week.

The official regulatory profile for domperidone is structured around avoiding combinations that significantly increase drug exposure and mitigating additive cardiac risks. This framework dictates mandatory prohibitions and constraints for co-administration.

Prohibited Combinations and Drug Exposure

Co-administration is strictly contraindicated with potent CYP3A4 inhibitors, such as systemic azole antifungals (e.g., ketoconazole) and certain macrolide antibiotics (e.g., clarithromycin). This prohibition is due to the pharmacokinetic risk of these substances significantly raising domperidone plasma concentrations. Furthermore, all medicinal products formally known to prolong the QTc interval are strictly contraindicated, stemming from the additive pharmacodynamic risk to cardiac conduction.

Documented Interaction Constraints

Population-Specific Restrictions

The medicine is formally contraindicated in patients diagnosed with moderate or severe hepatic impairment (Child-Pugh B or C) due to compromised clearance leading to increased systemic exposure. For patients with severe renal impairment (creatinine clearance less than 30 mL/min), a formal reduction in dosing frequency is required, as the elimination half-life is significantly prolonged. The drug is also contraindicated in patients with underlying cardiac risk factors like significant electrolyte disturbances or bradycardia.

Domperidone functions as a peripheral dopamine D2 receptor antagonist. Its mechanism involves target engagement in both the stomach/upper gastrointestinal tract and the chemoreceptor trigger zone (CTZ). In the gastrointestinal tract, the blockade of peripheral D2 receptors modulates signaling to promote the release of acetylcholine from post-ganglionic cholinergic neurons. Increased acetylcholine release enhances the force and rate of peristalsis and increases the tone of the lower esophageal sphincter, resulting in enhanced gastric emptying. In the chemoreceptor trigger zone, antagonism of D2 receptors reduces afferent dopaminergic signaling. Domperidone is characterized by its minimal ability to cross the blood-brain barrier, restricting its primary pharmacological activity to the periphery.

Official Administration Principles

Domperidone is officially administered via the oral route, typically using 10 mg tablets or an oral suspension, or via the rectal route using 30 mg suppositories. The administration pattern adheres to the principle of using the drug for the shortest possible duration. For acute symptoms, treatment should not normally exceed one week (seven days), requiring formal re-evaluation if continued use is necessary.

Dosing and Contextual Rules

The standard regimen for adults and adolescents who weigh 35 kg or more involves a 10 mg dose per administration, taken up to three times per day. The maximum recommended daily oral dose is 30 mg. Oral Domperidone must be taken before meals, ideally 15–30 minutes prior to food intake, to ensure optimal absorption. A minimum interval of eight hours is advised between each oral dose.

For pediatric patients weighing less than 35 kg, the dose is calculated based on body weight, using 0.25 mg per kilogram of body weight per intake. Tablets must be swallowed whole with water. For patients with severe renal impairment, the dosing frequency must be reduced to once or twice daily to prevent drug accumulation. If a dose is missed, it should be omitted, and the usual schedule should be resumed; the dose must not be doubled to compensate.

Research Evidence / Overview of studies for Domperidone GSK

Evidence for Acute Nausea and Vomiting

Research exploring short-term changes in symptoms has primarily been conducted using short-term, randomized controlled trials (RCTs) in adults and adolescents (aged 12 and older). These studies examined the frequency of vomiting episodes and changes in patient-reported nausea symptoms, typically during the first 48 hours of treatment. Findings derived from this evidence structure describe patterns observed over very short, defined time intervals. Regulatory reviews indicate that the evidence structure for this acute, short-duration use in adults and older adolescents was evaluated. However, the available research structure provides limited insight into long-term or sustained use.

A multicenter, placebo-controlled study focused on children under 12 years old with acute gastroenteritis and studies in this population did not establish a difference from placebo when monitoring vomiting episodes. Following this, product information in many regulated markets was updated to reflect that the evidence structure for its use for nausea and vomiting in children younger than 12 years was determined to be insufficient.

Evidence for Motility Disorders and Digestive Discomfort

The research exploring Domperidone's use for symptoms associated with delayed gastric emptying, such as epigastric fullness or early satiety, is generally categorized as a Moderate to Low evidence level due to the structural characteristics of the studies. The evidence landscape comprises systematic reviews, smaller trials, and data from programs for patients whose condition had not adequately responded to standard therapies.

Studies examined changes in patient-reported GI symptoms using validated scales and also explored changes in the objective Gastric Emptying (GE) rate using methods like scintigraphy. The study populations primarily included adults with conditions characterized by functional limitations, such as diabetic or idiopathic gastroparesis. The evidence quality varies across studies; many reported outcomes were observed in studies that lacked a placebo control group, or they used modest sample sizes. Some systematic reviews conclude that the evidence remains limited and heterogeneous.

Long-Term Study Structures and Follow-up Durations

Follow-up durations for research examining motility-related symptoms vary, with some studies observing responses over defined time intervals that extend up to several months in certain cohorts. Long-term outcomes for most patients are not well characterized by controlled clinical trials. The data show patterns related to symptom changes in observational settings, but the evidence for use beyond the short-term is derived from studies with structural limitations that make definitive long-term conclusions challenging.

What is Still Uncertain About Domperidone GSK Evidence

The most significant limitation is the general lack of high-quality, long-term evidence for sustained use in chronic conditions, meaning long-term effects are not fully established. Research exploring short-term symptom changes in the acute setting provides limited insight into long-term safety or efficacy patterns. Evidence quality varies across studies, and comparative evidence against other available treatments for motility disorders is often lacking. This evidence highlights what is known—and what is still uncertain—about Domperidone's profile across its studied uses.

Key Studies & References

1. PRODUCT MONOGRAPH PrMAR-DOMPERIDONE (Authoritative Canadian document for motility and Parkinson's indications)

Common questions about Domperidone GSK (FAQ)

Q: Does Domperidone GSK treat motion sickness or just general nausea?

According to official product information, Domperidone is primarily indicated to relieve symptoms of nausea and vomiting, as well as certain digestive motility problems. It is not specifically listed in its main approved indications for the treatment of motion sickness.

Q: Is Domperidone GSK the same as Motilium?

Yes, Motilium is one of the trade names used in many regions globally for medicines that contain the active ingredient domperidone. Different companies or countries may market the same active medicine under various trade names.

Q: What is the typical timeframe before Domperidone GSK starts working?

Studies that look at how the medicine is absorbed in the body indicate that Domperidone reaches its highest level in the blood (peak plasma concentration) about one hour after it's taken orally. This timing is described as being linked to when the effects of the medicine begin.

Q: How long does the effect of one dose of Domperidone GSK usually last?

Regulatory data on the drug's elimination (pharmacokinetics) show that the elimination half-life in healthy adults is approximately 7.5 hours. This measure helps inform how long the medicine is present in the body.

Q: Are changes in menstrual cycles a possible side effect of Domperidone GSK?

Official product information lists that menstrual periods may become irregular or stop completely (a condition called amenorrhoea) as a reported side effect. This is because the medicine can increase levels of the hormone prolactin in the body, which can affect the reproductive system.

Q: Does Domperidone GSK interact with common over-the-counter pain medicines?

Official product documents do not typically list specific interactions with common over-the-counter pain relievers. However, regulatory documents describe constraints against using the medicine with certain drugs, such as those that affect the CYP3A4 enzyme or those known to prolong the QTc interval in the heart.

Q: What types of foods or drinks, such as grapefruit, should be avoided with Domperidone GSK?

Official guidance states that foods or drinks that are potent inhibitors of the CYP3A4 enzyme should be avoided, as they can increase the concentration of domperidone in the blood. Guidance specifies that grapefruit or grapefruit juice falls into this category.

Q: Is there a risk of developing a serious condition called tardive dyskinesia from Domperidone GSK?

Uncontrolled movements, including tardive dyskinesia, have been rarely associated with Domperidone in official product information. This risk may increase with higher doses or longer use than recommended.

Q: Does Domperidone GSK cause drowsiness or affect a person's ability to drive?

Official product information states that the medicine can cause drowsiness (somnolence) or dizziness. Because of this, it may affect a person's ability to safely drive or operate heavy machinery. The official label cautions that users should be aware of these potential effects.

Q: Is Domperidone GSK available for use in all countries?

No. The regulatory status of Domperidone varies globally. For example, while the medicine is approved in many countries (e.g., Canada, Australia, UK), it is not approved for general use in the United States by the U.S. Food and Drug Administration (FDA).

Q: Can Domperidone GSK cause withdrawal symptoms if stopped suddenly after long-term use?

The medicine is designed for short-term use, and prolonged use is discouraged by regulatory authorities. However, some individuals, particularly those who have been on prolonged therapy or used the medicine outside of recommended guidelines, have reported experiencing certain psychiatric or physical withdrawal symptoms when stopping the medicine abruptly.

Q: What evidence exists about Domperidone GSK's effectiveness in increasing milk production?

Domperidone is not approved for the purpose of increasing milk production (galactagogue use); its official indication is for nausea and vomiting. Studies have examined this effect and indicate that the medicine can increase prolactin levels. However, the medicine is generally not recommended for use in breastfeeding mothers due to official safety constraints.

Q: How much Domperidone GSK passes into breast milk?

Regulatory reviews show that very small amounts of domperidone pass into breast milk. While the amount is considered low, regulatory information advises against its use in breastfeeding mothers due to safety concerns.

Q: Has Domperidone GSK been studied for use in specific populations, such as people with Parkinson's disease?

Yes, Domperidone is sometimes used to help treat the nausea and vomiting that may be caused by other medications used for Parkinson's disease. This is because the medicine has a unique characteristic of affecting dopamine receptors primarily outside the brain, minimizing its interference with other central nervous system treatments.

Q: What is known about the safety of Domperidone GSK use during pregnancy?

Official product information indicates that there is limited data on Domperidone's use in pregnant women. Regulatory documents describe that the medicine is reserved for use during pregnancy only when the potential benefits are judged to outweigh the potential risks.

Q: What is the proper way to stop taking Domperidone GSK after long-term treatment?

Official guidelines recommend treatment for the shortest possible duration (typically no more than one week). For patients who have used the medicine for a prolonged period, some clinical reports describe using a slow, gradual reduction in dose (taper) to help minimize the risk of experiencing any withdrawal symptoms.

Q: Are there any reported side effects of Domperidone GSK on fertility?

Official labeling generally does not list effects on fertility directly. However, the medicine is known to increase prolactin levels, which can affect the hormonal balance necessary for normal reproductive function in both men and women.

Q: Is Domperidone GSK approved by the FDA?

The medicine is not approved for general marketing or sale in the United States by the U.S. Food and Drug Administration (FDA).

Q: Can Domperidone GSK be taken with alcohol?

Official patient information generally indicates that avoiding alcohol while taking Domperidone is appropriate. Alcohol may worsen certain side effects of the medicine, such as drowsiness, and may increase the risk of an irregular heartbeat.

Q: What are the symptoms of an allergic reaction to Domperidone GSK?

Symptoms of a severe allergic reaction (anaphylaxis) are listed in official documents and can include a rash, hives, swelling of the face, lips, or throat, or having difficulty breathing. These symptoms represent a serious adverse reaction.

Q: How quickly should someone see an increase in milk supply when using Domperidone GSK?

For the off-label purpose of increasing milk supply, clinical research reviews have noted that an increase in milk production was reported by patients starting treatment around the 48-hour mark.

Q: Does Domperidone GSK affect the action of oral contraceptives?

Official regulatory documents do not specifically list an interaction between Domperidone and oral contraceptives. However, caution is advised when using any drug that might affect the body’s metabolic processes of other medications.

Q: Is there evidence of Domperidone GSK causing weight gain?

Weight gain is not listed as a common or uncommon side effect in the official Summary of Product Characteristics (SmPC). However, some patient post-market surveys have included reports of this side effect.

Q: What are the regulations surrounding the use of Domperidone GSK in different regions, like the UK or Canada?

Regulations concerning the use of the medicine differ by country. For example, jurisdictions such as the UK and Canada have approved formulations but enforce strict rules regarding patient eligibility, the maximum allowable daily dose (e.g., 30 mg/day), and the duration of treatment allowed.

Q: Is it normal to feel restless or have muscle spasms when starting Domperidone GSK?

Uncontrolled movements, which include muscle spasms, excessive trembling, or restlessness (akathisia), have been reported as side effects. Official guidance indicates that if these movement side effects occur, the medicine may need to be discontinued.

Storage and Disposal Requirements

Connection to the overall storage/disposal profile:

Regulatory documents define the storage profile of Domperidone by establishing a maximum temperature constraint (below 30 C) and mandating protection from environmental factors such as light and moisture. Storage rules are enforced through requirements to keep the medicine in its original, tightly closed packaging and strictly out of the reach of children. Disposal guidelines consistently direct users to utilize official pharmaceutical waste procedures, such as take-back programs, rather than discarding the product into household waste or down the drain [2.5].